Prelude Capital Management, LLC Bristol Myers Squibb CO Call Options Transaction History

Prelude Capital Management, LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2022 Feb 14, 2023	BUY	$68.48 - $81.09 $287,616 - $340,578	4,200 New	4,200 $302,000
Q2 2022 Aug 15, 2022	SELL	$72.62 - $79.98 $413,934 - $455,886	-5,700 Reduced 32.02%	12,100 $932,000
Q1 2021 May 17, 2021	SELL	$59.34 - $66.74 $1.73 Million - $1.95 Million	-29,200 Reduced 62.13%	17,800 $1.12 Million
Q4 2020 Feb 16, 2021	BUY	$57.74 - $65.43 $1.27 Million - $1.44 Million	22,000 Added 88.0%	47,000 $32,000
Q3 2019 Nov 14, 2019	SELL	$42.77 - $50.71 $21.8 Million - $25.8 Million	-509,700 Reduced 95.32%	25,000 $1.27 Million
Q1 2019 May 15, 2019	BUY	$45.12 - $53.8 $21.9 Million - $26.1 Million	484,600 Added 967.27%	534,700 $25.5 Million
Q4 2018 Feb 14, 2019	SELL	$48.76 - $63.23 $1.21 Million - $1.57 Million	-24,900 Reduced 33.2%	50,100 $2.6 Million
Q3 2018 Nov 14, 2018	BUY	$55.19 - $62.25 $3.09 Million - $3.49 Million	56,000 Added 294.74%	75,000 $4.66 Million
Q1 2018 May 15, 2018	BUY	$59.92 - $68.98 $1.14 Million - $1.31 Million	19,000 New	19,000 $1.2 Million

2,428

1.5B

29.7M

32.2M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $113B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.